Neogenomics Inc. (NASDAQ: NEO) stock jumped 0.52% on Monday to $19.51 against a previous-day closing price of $19.41. With 0.82 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.93 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $19.57 whereas the lowest price it dropped to was $19.05. The 52-week range on NEO shows that it touched its highest point at $20.54 and its lowest point at $8.70 during that stretch. It currently has a 1-year price target of $21.00. Beta for the stock currently stands at 1.34.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NEO was up-trending over the past week, with a rise of 21.33%, but this was up by 40.36% over a month. Three-month performance surged to 38.57% while six-month performance rose 6.44%. The stock gained 95.49% in the past year, while it has gained 111.15% so far this year. A look at the trailing 12-month EPS for NEO yields -0.77 with Next year EPS estimates of -0.08. For the next quarter, that number is -0.03. This implies an EPS growth rate of 67.86% for this year and 57.69% for next year.
Float and Shares Shorts:
At present, 126.91 million NEO shares are outstanding with a float of 125.79 million shares on hand for trading. On Oct 30, 2023, short shares totaled 6.15 million, which was 4.83% higher than short shares on Sep 28, 2023. In addition to NIO as the firm’s NIO Inc., NVO serves as its Novo Nordisk A/S.
Institutional Ownership:
Through their ownership of 93.40% of NEO’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NEO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With NEO analysts setting a high price target of $30.00 and a low target of $16.00, the average target price over the next 12 months is $21.00. Based on these targets, NEO could surge 53.77% to reach the target high and fall by -17.99% to reach the target low. Reaching the average price target will result in a growth of 7.64% from current levels.
Summary of Insider Activity:
Insiders traded NEO stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 1,680 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has risen to 9 over the past year. The total number of shares bought during that period was 332,972 while 29,477 shares were sold.
